1.1Cellulose beads as cores
An aqueous starch dispersion wets the cellulose beads during tumbling. Zinc oxide powder deposits on the wet beads, and drying fixes the powder to their surfaces.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An aqueous starch dispersion wets the cellulose beads during tumbling. Zinc oxide powder deposits on the wet beads, and drying fixes the powder to their surfaces.
An aqueous sodium hyaluronate solution wets the hydroxylated alumina surface. Titanium dioxide powder contacts the wetted spheres during mixing, and drying leaves a polymer film holding the powder in place.
An aqueous starch primer dries on silica particles before an organic coating is applied. An ethyl cellulose solution containing dissolved octocrylene coats the primed particles, and solvent evaporation leaves a film that absorbs ultraviolet radiation.
An aqueous butyl acrylate and methyl methacrylate copolymer latex wets the silica cores. Titanium dioxide powder adheres to the wet cores, and drying above the latex film formation temperature forms polymer bridges between the silica and titanium dioxide.
Zinc oxide seeds form on hydroxylated silica cores during a zinc salt deposition step. A heated aqueous zinc nitrate and hexamethylenetetramine bath grows the attached seeds into a shell of zinc oxide crystallites.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Silica cores carry a shell of rutile titanium dioxide held in place by starch. A waterborne acrylic binder disperses the particles in a coating applied to the exterior face of paperboard with a metering rod. Drying fixes the particles in the film, where the titanium dioxide shell attenuates ultraviolet radiation incident on the board.
Chitosan replaces hyaluronic acid and starch as the binder between silica cores and a titanium dioxide powder shell. An aqueous chitosan solution adjusted to pH 5 with acetic acid deposits protonated chitosan onto the silica surface. The coated cores are separated from excess solution, mixed with an aqueous titanium dioxide dispersion, and dried to fix the powder to the cores.
Hexagonal boron nitride platelets replace zinc oxide and titanium dioxide as the inorganic shell powder. Silica microspheres receive a coating of gelatinized starch, and low-shear tumbling brings the platelets into contact with the moist coating. Drying fixes the platelets to the spheres, and the exposed platelet faces form low-friction contacts in a pressed cosmetic powder.
Silica cores with a median diameter of 40 micrometres are fluidized in air at 45 to 55 degrees Celsius while a slurry of gelatinized starch and rutile titanium dioxide is sprayed onto them. The slurry uses a 9-to-1 dry mass ratio of titanium dioxide to starch. Separate batches reach dry mass gains of 10, 20, and 30 grams per 100 grams of starting silica to vary shell loading while holding the slurry composition constant.
Silica cores carry a zinc oxide powder shell bonded with starch and are dispersed in an aqueous gel thickened with xanthan gum. The gum is hydrated in water before the composite particles are folded into the gel with a low-speed paddle. The gel provides yield stress to limit sedimentation at rest and shear-thins during spreading to distribute the particles across the applied film.
A mixer sprays gelatinized starch onto silica cores and meters titanium dioxide powder into the moving bed. An automated sampler spreads dried aliquots into a single particle layer, and a reflected-light microscope records the particles under fixed illumination. Software estimates shell coverage from calibrated images of bare and coated cores, and the controller stops powder feed when the median coverage reaches the setpoint.
Spray drying a colloidal silica dispersion produces spherical cores made of aggregated silica particles. Sieving collects cores between 20 and 45 micrometers for subsequent coating.
Rutile titanium dioxide and zinc oxide powders are dry blended before application to binder-wetted silica cores. Tumbling distributes the two oxides over the core surfaces, and drying fixes the mixed powder shell.
A fluidized bed coater sprays an aqueous hyaluronic acid solution onto silica cores and feeds titanium dioxide powder into the bed. Warm air removes water, leaving binder bridges between the cores and the powder particles.
Pregelatinized maize starch disperses in room-temperature water to form a binder feed. The feed wets the silica cores and forms a film that anchors zinc oxide powder as the particles dry.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl.A · US 2016/0361268 A1 · abstract
The polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) can be derived from microbial fermentation or animal tissue.B · US 2018/0289735 A1 · ¶ 83
An empty cell means only that no passage was reproduced there.
Treatment of lymphatic metastatic tumors remains a great challenge given the limitations of surgical resection and the low effectiveness of radiotherapy and chemotherapy (Zhang, X., Lu, W. “Recent advances in lymphatic targeted drug delivery system”, Cancer Biol.A · US 2016/0361268 A1 · ¶ 3
Disclosed is a method of treating lymphatic cancer using hyaluronan nanoparticles.A · US 2016/0361268 A1 · ¶ 7
A method to treat and alleviate symptoms of joint pain in an animal includes administering to the animal a therapeutic amount of a dietary supplement composition comprising hyaluronic acid/hyaluronan, including pro-inflammatory low molecular weight sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) in an oral dosage form.B · US 2018/0289735 A1 · ¶ 5
In yet another example, the hyaluronic acid/hyaluronan may include hyaluronic acid/hyaluronan having a molecular weight greater than the 0.5 to 300 kDa range.B · US 2018/0289735 A1 · ¶ 7
patent.fyi, US 2026/0355070 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355070/, SHA-256 24a80b898d493b92159d02a0f4a66b6288853f0f183ea462a70547d54be99ecd